The Latest Breaking News from Insulet

Insulet has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.

Insulet is scheduled to release its fiscal fourth-quarter earnings next month, and analysts project a double-digit profit decline.

Insulet has outperformed the Dow recently, and analysts remain strongly optimistic about the stock’s prospects.

As Insulet outperformed relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Dexcom and ŌURA have partnered to integrate Dexcom's glucose biosensing feature with the ŌURA Ring's health metrics to help improve consumers' metabolic health.

Pharmac’s decision to fund continuous glucose monitors and automated insulin delivery systems for the approximately 18,000 people who currently live with type 1 diabetes in Aotearoa New Zealand is good news.

Insulet has outperformed the Nasdaq Composite over the past year and analysts remain strongly bullish about the stock’s prospects.

The Nasdaq 100 fell to a 2-week low on Wednesday, dragging down the broader market. Nvidia stock drops after the AI company released its earnings report.

The Nasdaq 100 fell to a 2-week low on Wednesday, dragging down the broader market. Nvidia stock drops after the AI company released its earnings report.

The S&P 500 Index ($SPX ) (SPY ) Wednesday closed down -0.60%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.18%. Stocks settled lower Wednesday, with the Nasdaq 100 falling to a 2-week low. Weakness...

The S&P 500 Index ($SPX ) (SPY ) today is down -0.27%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.03%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.81%. Weakness in chip stocks is weighing on the overall market ahead of quarterly earnings...